[
  {
    "ts": "2026-02-11T01:31:00+00:00",
    "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "summary": "Could these two companies be biotech giants in the making?",
    "url": "https://www.fool.com/investing/2026/02/10/missed-out-on-eli-lilly-2-healthcare-stocks-with-b/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "443a253e-838d-3f59-b49f-eb855f1a4d69",
      "content": {
        "id": "443a253e-838d-3f59-b49f-eb855f1a4d69",
        "contentType": "STORY",
        "title": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
        "description": "",
        "summary": "Could these two companies be biotech giants in the making?",
        "pubDate": "2026-02-11T01:31:00Z",
        "displayTime": "2026-02-11T01:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/311dc6a28d643b0bf2671d7d68071583",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Person injecting a GLP-1 drug into their upper arm.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IuM39n9wWtp1xvZdb6iZ8Q--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/311dc6a28d643b0bf2671d7d68071583.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zEIN08ZuRqyC97nHHAd5Dg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/311dc6a28d643b0bf2671d7d68071583.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/10/missed-out-on-eli-lilly-2-healthcare-stocks-with-b/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/missed-eli-lilly-2-healthcare-013100642.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T04:34:49+00:00",
    "headline": "Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued",
    "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Innovent Biologics to co develop new oncology and immunology drugs for global markets. Both transactions are aimed at broadening Lilly's pipeline beyond its existing focus areas of obesity and diabetes. For you as an investor, these deals...",
    "url": "https://finance.yahoo.com/news/eli-lilly-broadens-genetic-medicine-043449819.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "029b90f7-5bbc-3b06-94ae-c2b07214953f",
      "content": {
        "id": "029b90f7-5bbc-3b06-94ae-c2b07214953f",
        "contentType": "STORY",
        "title": "Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to expand its genetic medicine and in vivo cell therapy efforts, focused on engineered circular RNA and autoimmune disease targets. The company also entered a multi billion dollar collaboration with Innovent Biologics to co develop new oncology and immunology drugs for global markets. Both transactions are aimed at broadening Lilly's pipeline beyond its existing focus areas of obesity and diabetes. For you as an investor, these deals...",
        "pubDate": "2026-02-11T04:34:49Z",
        "displayTime": "2026-02-11T04:34:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-broadens-genetic-medicine-043449819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-broadens-genetic-medicine-043449819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T06:35:00+00:00",
    "headline": "Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore",
    "summary": "This stock has been known to soar after good news.",
    "url": "https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "0099994a-1982-3bb2-8b6f-a6988cdcbe06",
      "content": {
        "id": "0099994a-1982-3bb2-8b6f-a6988cdcbe06",
        "contentType": "STORY",
        "title": "Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore",
        "description": "",
        "summary": "This stock has been known to soar after good news.",
        "pubDate": "2026-02-11T06:35:00Z",
        "displayTime": "2026-02-11T06:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/48a1f3ca98aa348f63fddfd1e458fb76",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A group of investors cheers in an office.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jvp4kwbYQI1HSof4LKBy9g--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/48a1f3ca98aa348f63fddfd1e458fb76.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VQUeqlC8f4I4304.THwjQA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/48a1f3ca98aa348f63fddfd1e458fb76.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-under-radar-glp-063500953.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T05:41:38+00:00",
    "headline": "The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call",
    "summary": "Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong contribution from Mounjaro and Zepbound, noting that volume growth in these products was the primary driver of revenue gains. CEO David Ricks underscored the impact of new product launches and expanded manufacturing capacity, stating, “We delivered robust revenue growth, advanced our pipeline, expande",
    "url": "https://finance.yahoo.com/news/top-5-analyst-questions-eli-054138431.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "88005a70-ad81-39f4-b82c-137a68eace59",
      "content": {
        "id": "88005a70-ad81-39f4-b82c-137a68eace59",
        "contentType": "STORY",
        "title": "The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call",
        "description": "",
        "summary": "Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong contribution from Mounjaro and Zepbound, noting that volume growth in these products was the primary driver of revenue gains. CEO David Ricks underscored the impact of new product launches and expanded manufacturing capacity, stating, “We delivered robust revenue growth, advanced our pipeline, expande",
        "pubDate": "2026-02-11T05:41:38Z",
        "displayTime": "2026-02-11T05:41:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "LLY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7jUkGcVljBpqcrgSnimZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fw6rZdJZ6CRFkLxhDmPhew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-eli-054138431.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-eli-054138431.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T15:35:00+00:00",
    "headline": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
    "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
    "url": "https://www.fool.com/investing/2026/02/11/healthcare-stock-sink-buy-dip-pfe-lly-nvo/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f672f5cd-120a-3c48-b229-0fb9c3715316",
      "content": {
        "id": "f672f5cd-120a-3c48-b229-0fb9c3715316",
        "contentType": "STORY",
        "title": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
        "description": "",
        "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
        "pubDate": "2026-02-11T15:35:00Z",
        "displayTime": "2026-02-11T15:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Weight loss drugs in a box.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HOakPIrPMZzDxJsu3ZTwFA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xNt10sy25xjDsXix7qMQcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/11/healthcare-stock-sink-buy-dip-pfe-lly-nvo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/healthcare-stocks-sinking-2-buy-153500199.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T16:35:00+00:00",
    "headline": "3 Reasons to Buy Eli Lilly Stock",
    "summary": "The healthcare leader looks increasingly unstoppable.",
    "url": "https://www.fool.com/investing/2026/02/11/3-reasons-to-buy-eli-lilly-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f51f46e1-ff81-3efe-8c62-d7f3f4a045c5",
      "content": {
        "id": "f51f46e1-ff81-3efe-8c62-d7f3f4a045c5",
        "contentType": "STORY",
        "title": "3 Reasons to Buy Eli Lilly Stock",
        "description": "",
        "summary": "The healthcare leader looks increasingly unstoppable.",
        "pubDate": "2026-02-11T16:35:00Z",
        "displayTime": "2026-02-11T16:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2b9ca31f470bb1e0aa7c523a00042f24",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "Person raising both fists in the air.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4cw_pTqLFnYj2VGgQWEuxg--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2b9ca31f470bb1e0aa7c523a00042f24.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NS1JstFAgQjylUjEJa1S.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2b9ca31f470bb1e0aa7c523a00042f24.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/11/3-reasons-to-buy-eli-lilly-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-buy-eli-lilly-163500366.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T14:54:00+00:00",
    "headline": "Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?",
    "summary": "NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.",
    "url": "https://finance.yahoo.com/news/novo-nordisks-turnaround-story-risk-145400550.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "85231f4c-9afa-3eac-808b-06c1383c5f3e",
      "content": {
        "id": "85231f4c-9afa-3eac-808b-06c1383c5f3e",
        "contentType": "STORY",
        "title": "Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?",
        "description": "",
        "summary": "NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.",
        "pubDate": "2026-02-11T14:54:00Z",
        "displayTime": "2026-02-11T14:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OpV4giEb4QjgN71LPYFzIw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QcLiFahMpkHBfBp4mOYpEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-turnaround-story-risk-145400550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-turnaround-story-risk-145400550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T17:57:52+00:00",
    "headline": "Pharma companies left out of Trump's drug-pricing deals look for way in",
    "summary": "SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U. drug pricing are looking to craft their own deals in an attempt to avoid potentially onerous tariffs and new price-setting schemes, according to six industry sources.",
    "url": "https://finance.yahoo.com/news/pharma-companies-left-trumps-drug-175752008.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "867b6805-b934-30c9-9735-f250343c9494",
      "content": {
        "id": "867b6805-b934-30c9-9735-f250343c9494",
        "contentType": "STORY",
        "title": "Pharma companies left out of Trump's drug-pricing deals look for way in",
        "description": "",
        "summary": "SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U. drug pricing are looking to craft their own deals in an attempt to avoid potentially onerous tariffs and new price-setting schemes, according to six industry sources.",
        "pubDate": "2026-02-11T17:57:52Z",
        "displayTime": "2026-02-11T17:57:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/9902c3ca51e94143ba464aa29282f32d",
          "originalWidth": 800,
          "originalHeight": 498,
          "caption": "FILE PHOTO: U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9fCNKUK2NoJafrqqtTLEJg--~B/aD00OTg7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/9902c3ca51e94143ba464aa29282f32d.cf.webp",
              "width": 800,
              "height": 498,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aW0WyMBhWSLx5BrfWjUPNg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/9902c3ca51e94143ba464aa29282f32d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharma-companies-left-trumps-drug-175752008.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-companies-left-trumps-drug-175752008.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "ALKS"
            },
            {
              "symbol": "ALNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T19:26:28+00:00",
    "headline": "Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of February 6, 2026, robust demand for the company’s obesity and diabetes treatments continues to drive strong investor sentiment. Eli Lilly and Company (NYSE:LLY)’s shares have gained roughly 70% in the past […]",
    "url": "https://finance.yahoo.com/news/robust-demand-eli-lilly-company-192628926.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a8fd8d87-13ba-3c9a-9af7-e81a034aeb97",
      "content": {
        "id": "a8fd8d87-13ba-3c9a-9af7-e81a034aeb97",
        "contentType": "STORY",
        "title": "Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of February 6, 2026, robust demand for the company’s obesity and diabetes treatments continues to drive strong investor sentiment. Eli Lilly and Company (NYSE:LLY)’s shares have gained roughly 70% in the past […]",
        "pubDate": "2026-02-11T19:26:28Z",
        "displayTime": "2026-02-11T19:26:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2f78fead5594bb342fb5f189e04643d0",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4wpwPe7EqPNXMa5dQD.4IA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2f78fead5594bb342fb5f189e04643d0.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t2QVJrZnoS6VqtL1iFGAPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2f78fead5594bb342fb5f189e04643d0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/robust-demand-eli-lilly-company-192628926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/robust-demand-eli-lilly-company-192628926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T21:14:00+00:00",
    "headline": "Top Analyst Reports for Eli Lilly, Marriott & Fortinet",
    "summary": "Eli Lilly's Q4 beat and soaring GLP-1 demand lead top analyst picks, alongside fresh insights on Marriott and Fortinet's latest results.",
    "url": "https://finance.yahoo.com/news/top-analyst-reports-eli-lilly-211400476.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f5dbb4d6-f828-3e88-b422-ec42c5548e03",
      "content": {
        "id": "f5dbb4d6-f828-3e88-b422-ec42c5548e03",
        "contentType": "STORY",
        "title": "Top Analyst Reports for Eli Lilly, Marriott & Fortinet",
        "description": "",
        "summary": "Eli Lilly's Q4 beat and soaring GLP-1 demand lead top analyst picks, alongside fresh insights on Marriott and Fortinet's latest results.",
        "pubDate": "2026-02-11T21:14:00Z",
        "displayTime": "2026-02-11T21:14:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/004265dfd2737a0262868ee5a83c126c",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BAtSvwvwTDUAYvcNvazb.g--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/004265dfd2737a0262868ee5a83c126c.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8xo3tDqasnFq4dq2S2LupQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/004265dfd2737a0262868ee5a83c126c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-analyst-reports-eli-lilly-211400476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-analyst-reports-eli-lilly-211400476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "FTNT"
            },
            {
              "symbol": "MAR"
            },
            {
              "symbol": "GSIT"
            },
            {
              "symbol": "KEQU"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]